Karl Mahler - Roche Holding Head of Investor Relations
| RHHBF Stock | USD 275.03 7.20 2.69% |
Executive
Karl Mahler is Head of Investor Relations of Roche Holding AG
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Reed | Roche Holding Ltd | 59 | |
| Eva Tubau | Grifols SA ADR | N/A | |
| George Gunn | Novartis AG ADR | 63 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Vicente Torre | Grifols SA ADR | 63 | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Sophie KornowskiBonnet | Roche Holding Ltd | 54 | |
| Susanne Fiedler | Organon Co | 56 | |
| FranoisXavier Roger | Sanofi ADR | 62 | |
| Rebecca Edwards | Organon Co | N/A | |
| Linda MD | Novartis AG ADR | 61 | |
| Natalie Bickford | Sanofi ADR | 54 | |
| Madeleine Roach | Sanofi ADR | 40 | |
| Thomas Larsen | AstraZeneca PLC ADR | N/A | |
| Vasant MD | Novartis AG ADR | 48 | |
| Daniel Karp | Organon Co | 46 | |
| John Tsai | Novartis AG ADR | 54 | |
| Aaron Falcione | Organon Co | 52 | |
| Vittorio Nisita | Organon Co | 55 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Head of Group HR | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, General Counsel and Corporate Secretary | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, COO of Pharmaceuticals division | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, CFO and IT Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, CEO and Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 287.91 B | |||
| Shares Outstanding | 106.69 M | |||
| Shares Owned By Insiders | 75.31 % | |||
| Shares Owned By Institutions | 8.56 % | |||
| Price To Earning | 21.63 X | |||
| Price To Book | 11.61 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding AG information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |